FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 315:405-411 August 14, 1986 Number 7 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To investigate the effect of individual formulations of oral contraceptives on the risk of breast cancer in women, we analyzed case-control data from the Cancer and Steroid Hormone Study of the Centers for Disease Control. The cases were 4711 women 20 to 54 years old with newly diagnosed breast cancer who were selected from eight population-based cancer registries. The controls were 4676 women selected by random-digit dialing of the population of each area covered by a registry. As compared with women who had never used oral contraceptives, women who had used them had a relative risk of breast cancer of 1.0. Among women who used only one oral-contraceptive formulation, this estimate of relative risk did not change appreciably according to the formulation used. Neither the type of estrogen nor the type of progestin contained in oral contraceptives used was associated with an increased risk of breast cancer. The duration of oral-contraceptive use and the time since last use did not influence the risk. These findings provide further support for the contention that oral-contraceptive use does not increase the risk of breast cancer in women.

This article has been cited by other articles:

• Wingo, P. A., Austin, H., Marchbanks, P. A., Whiteman, M. K., Hsia, J., Mandel, M. G., Peterson, H. B., Ory, H. W. (2007). Oral Contraceptives and the Risk of Death From Breast Cancer. Obstet Gynecol 110: 793-800 [Abstract] [Full Text]  
• Fisher, W. A., Black, A. (2007). Contraception in Canada: a review of method choices, characteristics, adherence and approaches to counselling. CMAJ 176: 953-961 [Abstract] [Full Text]  
• Dunn, B. K., Wickerham, D. L., Ford, L. G. (2005). Prevention of Hormone-Related Cancers: Breast Cancer. JCO 23: 357-367 [Abstract] [Full Text]  
• Whiteman, M. K., Hillis, S. D., Curtis, K. M., McDonald, J. A., Wingo, P. A., Marchbanks, P. A. (2004). Reproductive History and Mortality After Breast Cancer Diagnosis. Obstet Gynecol 104: 146-154 [Abstract] [Full Text]  
• Seibert, C., Barbouche, E., Fagan, J., Myint, E., Wetterneck, T., Wittemyer, M. (2003). Prescribing Oral Contraceptives for Women Older Than 35 Years of Age. ANN INTERN MED 138: 54-64 [Abstract] [Full Text]  
• Farquhar, D. (2002). Oral contraceptives and the risk of breast cancer. CMAJ 167: 782-782 [Full Text]  
• Davidson, N. E., Helzlsouer, K. J. (2002). Good News about Oral Contraceptives. NEJM 346: 2078-2079 [Full Text]  
• Lebow, M. A. (1999). THE PILL AND THE PRESS: REPORTING RISK. Obstet Gynecol 93: 453-456 [Abstract] [Full Text]  
• Frank, T. S. (1998). Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist. The Oncologist 3: 403-412 [Abstract] [Full Text]  
• Baird, D. T., Glasier, A. F. (1993). Hormonal Contraception. NEJM 328: 1543-1549 [Full Text]